Literature DB >> 8199011

Characterization of a murine model of myocarditis induced by a reactivated coxsackievirus B3.

H Zhang1, G E Yousef, X Ouyang, L C Archard.   

Abstract

A transfection-reactivated Coxsackievirus B3 (rCVB3), from a full-length cDNA clone of Nancy strain, has previously been shown to be as cardiovirulent as the wild-type virus. Myocarditis induced by this genetically defined virus was compared in SWR mice with the traditional Balb/c model. SWR mice inoculated with rCVB3 developed more severe myocarditis but less severe pancreatitis than Balb/c mice. In contrast to the poor general health and frequent mortality of Balb/c mice following CVB3 infection, the body weight of SWR mice was not affected by CVB3 inoculation and no mortality occurred at titres of 10(2)-10(7) plaque forming units (PFU). Typical myocarditis developed in SWR mice 7 days post infection. Myocarditic foci consisting of necrotic myocardial fibres and mononuclear cell infiltrates resolved by day 30, similar to that observed in Balb/c. However, SWR mice were more sensitive to rCVB3-induced myocarditis than were Balb/c mice: mild myocarditis was induced (4/4) by as low as 10(2) PFU of the virus (ID50 < 10(1.5) PFU), and more severe myocarditis was seen at higher PFU of virus in a dose-dependent manner. The SWR model was tested with attenuated variants derived from cardiovirulent rCVB3. The ID50 for myocarditis was 10(7) PFU for a large plaque-size attenuant and 10(6) PFU for a minute plaque-size attenuant, indicating loss of cardiovirulence by a factor of more than 10(4)-10(5). rCVB3-induced SWR mouse is a sensitive and reliable model for myocarditis. It is useful in assessing the cardiovirulence of different CVB3 variants and evaluating the efficacies of anti-viral therapies. It will allow follow-up study after high dose infection with cardiovirulent rCVB3.

Entities:  

Mesh:

Year:  1994        PMID: 8199011      PMCID: PMC2002107     

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  34 in total

1.  COXSACKIE VIRUS B3 MYOCARDITIS IN MICE. AN ELECTRON MICROSCOPIC, IMMUNOFLUORESCENT AND VIRUS-ASSAY STUDY.

Authors:  E R RABIN; S A HASSAN; A B JENSON; J L MELNICK
Journal:  Am J Pathol       Date:  1964-05       Impact factor: 4.307

2.  Assessment of coxsackievirus B3 ts mutants for induction of myocarditis in a murine model.

Authors:  M D Trousdale; R E Paque; T Nealon; C J Gauntt
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

Review 3.  Virus myocardiopathy.

Authors:  A M Lerner; F M Wilson
Journal:  Prog Med Virol       Date:  1973

4.  Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease.

Authors:  J F Woodruff; J J Woodruff
Journal:  J Immunol       Date:  1974-12       Impact factor: 5.422

5.  The so-called Swiss mouse.

Authors:  C J Lynch
Journal:  Lab Anim Care       Date:  1969-04

Review 6.  Viral myocarditis. A review.

Authors:  J F Woodruff
Journal:  Am J Pathol       Date:  1980-11       Impact factor: 4.307

7.  Differing cardiotropic and myocarditic properties of group B type 4 coxsackievirus strains.

Authors:  Y Cao; D P Schnurr; N J Schmidt
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

8.  Experimental coxsackie B viral myocarditis in cynomolgus monkeys.

Authors:  T Hoshino; C Kawai; M Tokuda
Journal:  Jpn Circ J       Date:  1983-01

9.  Molecular cloning of the genome of a cardiotropic Coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells.

Authors:  R Kandolf; P H Hofschneider
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

10.  Characterization and myocarditic capabilities of coxsackievirus B3 variants in selected mouse strains.

Authors:  C J Gauntt; P T Gomez; P S Duffey; J A Grant; D W Trent; S M Witherspoon; R E Paque
Journal:  J Virol       Date:  1984-11       Impact factor: 5.103

View more
  4 in total

1.  Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.

Authors:  H Zhang; P Morgan-Capner; N Latif; Y A Pandolfino; W Fan; M J Dunn; L C Archard
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

2.  Enterovirus related metabolic myopathy: a postviral fatigue syndrome.

Authors:  R J M Lane; B A Soteriou; H Zhang; L C Archard
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-10       Impact factor: 10.154

3.  A single amino acid substitution in the capsid protein VP1 of coxsackievirus B3 (CVB3) alters plaque phenotype in Vero cells but not cardiovirulence in a mouse model.

Authors:  H Zhang; N W Blake; X Ouyang; Y A Pandolfino; P Morgan-Capner; L C Archard
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Characterization of enterovirus isolates from patients with heart muscle disease in a selenium-deficient area of China.

Authors:  T Peng; Y Li; Y Yang; C Niu; P Morgan-Capner; L C Archard; H Zhang
Journal:  J Clin Microbiol       Date:  2000-10       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.